阅读说明：本技术 用于动员造血干细胞和祖细胞的给药方案 (Dosing regimens for mobilizing hematopoietic stem and progenitor cells ) 是由 德怀特·莫罗 帕特里克·C·法拉赫 安东尼·博伊坦诺 迈克尔·P·库克 凯文·A·冈卡夫斯 于 2018-12-06 设计创作，主要内容包括：本发明提供了可用于动员供体中的造血干细胞和祖细胞(hematopoietic stem and progenitor cells)的群体,以及可用于确定动员的细胞的样品是否适于释放用于离体扩增和/或治疗用途的组合物和方法。根据本文描述的组合物和方法,可以从供体抽取动员的造血干细胞和祖细胞并将其施用至患者,用于治疗多种干细胞紊乱,尤其包括造血系统疾病(hematopoietic diseases)、代谢紊乱、癌症和自身免疫性疾病。在某些实施方案中,本文描述的组合物和方法导致具有免疫抑制作用并能够降低移植物抗宿主病发生率的CD34<Sup>dim</Sup>细胞的群体的动员。(The present invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells (hematopoietic stem and promoter cells) in donors, and for determining whether a sample of mobilized cells is suitable for release for ex vivo expansion and/or therapeutic use. According to the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be drawn from a donor and administered to a patient for the treatment of a variety of stem cell disorders, including hematopoietic disorders (hematopoietic disorders), metabolic disorders, cancer, and autoimmune diseases, among others. In certain embodiments, the compositions and methods described herein result in CD34 having immunosuppressive effects and being capable of reducing the incidence of graft versus host disease dim Mobilization of a population of cells.)